| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | February 15, 2024 |
| Accession Number: | 0001193125-24-036591 | ||||||
| Submission Type: | POS AM | ||||||
| |||||||
Save time and jump to the most important pieces.
3 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)
4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)
4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)
SC 13D/A - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)
SC 13D/A - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)
SC 13D/A - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)
Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process SEATTLE, Dec. 19, 2023 /PRNewswire/ -- Impel Pharmaceuticals Inc. (OTCQX:IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is pursuing a sale of the Company and has entered into an agreement with JN BIDCO LLC to serve as the "stalking horse" bidder to acquire the Company and its assets.
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it has initiated an exploration of strategic alternatives. As part of this process, the Company plans to consider a wide range of options with a focus on maximizing shareholder value, including a potential sale of assets of the Company, a sale of all of the Company, a merger or other strategic transactions. As the Company explores strategic options, Impel continues to provide full commercial support
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of
EFFECT - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)
S-8 POS - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)
S-8 POS - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)
SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W. Kalb, CPA, as Chief Financial Officer, effective May 10, 2023. "Michael brings an outstanding track record of executive leadership in finance, capital raising, business development and operations management to Impel Pharmaceuticals," said Adrian Adams, Chairman of the Board and Chief Executive Officer of Impel Pharmaceuticals. "We are delighted to welcome Michael to Impel's leadership team and believe that
SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of Directors. Mr. Cline brings more than 30 years of experience in the biopharmaceutical industry, including extensive commercialization and operational expertise. The Company also announced the departure of H. Stewart Parker, with both changes to the Board effective immediately. "It is my pleasure to welcome Darren to the Impel Board of Directors," said Adrian Adams, Chairman of the Board and Chief Executiv
Cowen initiated coverage of Impel NeuroPharma with a rating of Outperform and set a new price target of $35.00
Wedbush initiated coverage of Impel NeuroPharma with a rating of Outperform and set a new price target of $21.00
Guggenheim initiated coverage of Impel NeuroPharma with a rating of Buy and set a new price target of $32.00
Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer
Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of
SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update. To access the live conference call, please register using the conference link: https://register.vevent.com/register. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the webcast and accompan
Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update. "We continued to see strong growth in Trudhesa® prescriptions as we moved i